Histone deacetylase inhibitors (Trichostatin A, MS-275, valproic acid) show efficacy in experimental models of muscle atrophy by suppressing the expression of atrophic genes Murf1 and Atrogin-1 [225,226,227]. This evidence concerns the gene FBXO32 and Atrophy.